MGC Pharmaceuticals has appointed Sciensus Rare as exclusive distributor of its CannEpil treatment, for refractory epilepsy, and CogniCann, for dementia and Alzheimer’s, in the UK, Denmark, France, Italy, Spain and Luxembourg.

Roby Zomer
MGC Pharma chief executive Roby Zomer

For the initial 12 months of the four-year term, Sciensus Rare will be subject to minimum purchase order requirements to maintain its exclusive distributor status.

The Netherlands-based international pharmaceutical company specialises in the provision of rare disease medicines through decentralised clinical trials and medical early-access programs.

MGC Pharma chief executive Roby Zomer said: “This is another important step in widening patient access to our pharmaceutical products, and puts in place a long-term plan to build the distribution networks required in Western Europe, one of the most important pharmaceutical markets in the world.”

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...